Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Shionogi & Co., Ltd., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and the Americas. Founded in 1878, Shionogi has a rich history marked by significant milestones, including the development of innovative treatments for infectious diseases and pain management.
The company is renowned for its core products, which include antiviral medications and analgesics, distinguished by their efficacy and safety profiles. Shionogi's commitment to research and development has positioned it as a leader in the pharmaceutical sector, with notable achievements in drug discovery and a strong pipeline of new therapies. With a focus on improving patient outcomes, Shionogi continues to make strides in addressing unmet medical needs globally.
+26 vs industry average
Shionogi’s score of 68 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has above-average carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Shionogi, a Pharmaceutical Preparation Manufacturing company headquartered in Japan, reported total emissions of approximately 242.2 million kg CO2e in 2024. This figure includes Scope 1 emissions of approximately 40.1 million kg CO2e, market-based Scope 2 emissions of approximately 23.0 million kg CO2e, and Scope 3 emissions of approximately 179.2 million kg CO2e.
Looking back, Shionogi's total emissions were approximately 214.9 million kg CO2e in 2023, approximately 223.1 million kg CO2e in 2022, and approximately 226.4 million kg CO2e in 2021.
Shionogi has established several climate commitments. The company aims to achieve net-zero emissions by 2050. Near-term targets include reducing Scope 1 and 2 GHG emissions by 46.2% by fiscal year 2030/31 from a fiscal year 2019/20 base year. Additionally, they aim to reduce Scope 3 GHG emissions from purchased goods and services by 20% by fiscal year 2030/31 from a fiscal year 2019/20 base year. These targets are validated by the Science Based Targets initiative (SBTi) and are consistent with reductions required to keep warming to 1.5°C. The company also aims to reduce Scope 1 and Scope 2 emissions to near zero by the middle of this decade.
2031
46.2% reduction in Scope 2
SHIONOGI commits to reduce absolute scope 1 and 2 GHG emissions 46.2% by FY2030/31 from a FY2019/20 base year.
2031
46.2% reduction in Scope 1
SHIONOGI commits to reduce absolute scope 1 and 2 GHG emissions 46.2% by FY2030/31 from a FY2019/20 base year.
2031
20% reduction in scope 3 total
SHIONOGI commits to reduce absolute scope 3 GHG emissions from purchased goods and services 20% by FY2030/31 from a FY2019/20 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Shionogi’s sustainability data and climate commitments
Data year: 2024
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more